Proteomic studies in breast cancer (Review)

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 735-743

  Qin, Xian Ju ^a   Ling, Bruce X ^b  

^a SHANGHAI EIGHTH PEOPLE'S HOSPITAL   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Breast cancer; Matrix assisted laser desorption ionization time of flight mass spectrometry; Proteomics; Surface enhanced laser desorption ionization time of flight mass spectrometry

Indexed keywords

APOLIPOPROTEIN A; BRADYKININ; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CALGRANULIN A; COMPLEMENT COMPONENT C4A; CYCLIN D; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYTOKERATIN 17; CYTOKERATIN 5; DISHEVELLED 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; FIBRINOGEN; FIBRINOPEPTIDE A; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MUCIN 1; MUCIN 3; PROTEIN BCL 2; PROTEIN P53; RAF PROTEIN; TUMOR MARKER; UBIQUITIN; UNINDEXED DRUG; UVOMORULIN;

BREAST CANCER; CANCER PROGNOSIS; CANCER TISSUE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY; TUMOR CELL; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 84856923225     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.573     Document Type: Review

References (85)

1. Andersson T, Johansson M, Bolmsjo G and James P: Automating MALDI sample plate loading. J Proteome Res 6: 894-896, 2007.
2. Fink-Retter A, Czerwenka K, Gschwantler KD, et al: Proteomics in mammary cancer research. Eur J Gynaecol Oncol 30: 635-639, 2009.
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
4. Ries LA, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review (http://seer.cancer.gov/csr/1975-2005). National Cancer Institute, 2008.
5. Bertucci F, Birnbaum D and Goncalves A: Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 5: 1772-1786, 2006.
6. Ma XJ, Dahiya S, Richardson E, et al: Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11: R7, 2009.
7. Galva ERC, Martins LMS, Ibiapina JO, et al: Breast cancer proteomics: a review for clinicians. J Cancer Res Clin Oncol 137: 915-925, 2011.
8. Görg A, Drews O, Lück C, et al: 2-DE with IPGs. Electrophoresis 30 (Suppl 1): 122-132, 2009.
9. Baak JPA, Janssen EAM, Soreide K and Heikkilae R: Genomics and proteomics-the way forward. Ann Oncol 16 (Suppl 2): 30-34, 2005.
10. Bertucci F and Goncalves A: Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncol 4: 271-287, 2008.
11. Hamrita B, Nassr HB, Chahed K and Chouchane L: Proteomics approaches: new technologies and clinical applications in breast carcinomas. Gulf J Oncolog 1: 36-44, 2011.
12. Haab BB: Antibody arrays in cancer research. Mol Cell Proteomics 4: 377-383, 2005.
13. Nesvizhskii AI: Protein identification by tandem mass spectrometry and sequence database searching. Methods Mol Biol 367: 87-119, 2007.
14. Keller B, Sui J, Whittal YR, et al: Interferences and contaminants encountered in modern mass spectrometry. Anal Chim Acta 627: 71-81, 2008.
15. Yates JR, Ruse CI and Nakorchevsky A: Proteomics by mass spectrometry: approaches, advances and applications. Annu Rev Biomed Eng 11: 49-79, 2009.
16. Nesvizhskii AI, Vitek O and Aebersold R: Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat Methods 4: 787-797, 2007.
17. Sutton CW, Rustogi N, Gurkan C, et al: Quantitative proteomic profiling of matched normal and tumor breast tissues. J Proteome Res 9: 3891-3902, 2010.
18. Bouchal P, Roumeliotis T, Hrstka R, et al: Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 8: 362-373, 2009.
19. Honrado E, Benitez J and Palacios J: Histopathology of BRCA1-and BRCA2-associated breast cancer. Crit Rev Oncol Hematal 59: 27-39, 2006.
20. Palacios J, Robles-Frias MJ, Castilla MA, et al: The molecular pathology of hereditary breast cancer. Pathobiology 75: 85-94, 2008.
21. Mangia A, Chiriatti A, Tommasi S, et al: BRCA1 expression and molecular alterations in familial breast cancer. Histol Histopathol 24: 69-76, 2009.
22. Reis-Filho JS and Tutt NA: Triple negative tumours: a critical review. Histopathology 52: 108-118, 2008.
23. Bhargava R, Beriwal S, McManus K and Dabbs DJ: CK5 is more sensitive than CK5/6 in identifying the 'basal-like' phenotype of breast carcinoma. Am J Clin Pathol 130: 724-730, 2008.
24. Korkola J and Gray JW: Breast cancer genomes-form and function. Curr Opin Genet Dev 20: 4-14, 2010.
25. Hudelist G, Singer CF, Pischinger KI, et al: Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics 6: 1989-2002, 2006.
26. Pan S, Aebersold R, Chen R, et al: Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 8: 787-797, 2009.
27. Braakman RB, Luider TM, Martens JW, et al: Laser capture microdissection applications in breast cancer proteomics. Methods Mol Biol 755: 143-154, 2011.
28. Umar A, Dalebou JC, Timmermans AM, et al: Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry. Proteomics 5: 2680-2688, 2005.
29. Sanders ME, Dias EC, Xu BJ, et al: Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J Proteome Res 7: 1500-1507, 2008.
30. Orre LM, Pernemalm M, Lengqvist J, et al: Up-regulation, modification and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling. Mol Cell Proteomics 6: 2122-2131, 2007.
31. Moreira JM, Ohlsson G, Rank FE and Celis JE: Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 4: 555-569, 2005.
32. Zurita M, Lara PC, Moral RD, et al: Hypermethylated 14-3-3-σ and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 10: 217, 2010.
33. Schultz J, Ibrahim SM, Vera J and Kunz M: 14-3-3σ gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. Mol Cancer 8: 53, 2009
34. Kabbage M, Chahed K, Hamrita B, et al: Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J Biomed Biotechnol 2008: 564127, 2008.
35. Kamradt MC, Lu M, Werner ME, et al: The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280: 11059-11066, 2005.
36. Moyano JV, Evans JR, Chen F, et al: Alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116: 261-270, 2006.
37. Li J, Orlandi R, White CN, et al: Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51: 2229-2235, 2005.
38. Belluco C, Petricoin EF, Mammano E, et al: Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in breast cancer. Ann Surg Oncol 14: 2470-2476, 2007.
39. Winden AWJ, Gast MCW, Beijnen JH, et al: Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med Genomics 2: 4, 2009.
40. Winden AWJ, Broek I, Gast MCG, et al: Serum degradome markers for the detection of breast cancer. J Proteome Res 9: 3781-3788, 2010.
41. Villanueva J, Shaffer DR, Philip J, et al: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284, 2006.
42. Winden AW, Krop EJ, Karedal MH, et al: Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum: a nested case-control study. BMC Cancer 11: 381, 2011.
43. Pietrowska M, Polanska J, Marczak L, et al: Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. J Transl Med 8: 66, 2010.
44. Schulz DM, Bollner C, Thomas G, et al: Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 8: 3430-3438, 2009.
45. Zakharchenko O, Greenwood C, Lewandowska A, et al: Meta-data analysis as a strategy to evaluate individual and common features of proteomic changes in breast cancer. Cancer Genomics Proteomics 8: 1-14, 2011.
46. Drake RR, Lisa H, Cazares LH, et al: Challenges to developing proteomic-based breast cancer diagnostics. OMICS 15: 251-259, 2011.
47. Foekens JA, Atkins D, Zhang Y, et al: Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24: 1665-1671, 2006.
48. Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192, 2006.
49. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al: Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8: 1079-1087, 2007.
50. Desmedt C, Giobbie-Hurder A, Neven P, et al: The gene expression grade index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics 2: 40, 2009.
51. Gast MCW, Tinteren HV, Bontenbal M, et al: Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer 8: 389, 2008
52. Ricolleau G, Charbonnel C, Lode L, et al: Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6: 1963-1975, 2006.
53. Zeidan BA and Townsend PA: SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 10: 107, 2008.
54. Baskin Y and Yigitbaşi T: Clinical proteomics of breast cancer. Curr Genomics 11: 528-536, 2010.
55. Nakagawa T, Huang SK, Martinez SR, et al: Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res 66: 11825-11830, 2006.
56. Leong S, Christopherson RI and Baxter RC: Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cell Physiol Biochem 20: 579-590, 2007.
57. Gast MC, van Dulken EJ, van Loenen TK, et al: Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. Int J Biol Markers 24: 130-141, 2009.
58. Brozkova K, Budinska E, Bouchal P, et al: Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 10: R48, 2008.
59. Goncalves A, Charafe-Jauffret E, Bertucci F, et al: Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7: 1420-1433, 2008.
60. Traub F, Jost M, Hess R, et al: Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest 86: 246-253, 2006.
61. Harigopal M, Heymann J, Ghosh S, et al: Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Res Treat 115: 77-85, 2009.
62. Hodgkinson VC, Eagle GL, Drew PJ, et al: Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett 294: 13-24, 2010.
63. Villeneuve DJ, Hembruff SL, Veitch Z, et al: cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 96: 17-39, 2006.
64. Maurya P, Meleady P, Dowling P and Clynes M: Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 27: 1247-1255, 2007.
65. Nakayama S, Torikoshi Y, Takahashi T, et al: Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res 11: R12, 2009.
66. Riley CP, Zhang X, Nakshatei H, et al: A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. J Transl Med 9: 80, 2011.
67. Kulasingam V and Diamandis EP: Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 6: 1997-2011, 2007.
68. Loi S, Haibe-Kains B, Majjaj S, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107: 10208-10213, 2010.
69. Colombo PE, Milanezi F, Weigelt B and Reis-Filho JS: Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 13: 212, 2011.
70. Liu Y, Liu H, Han B and Zhang JT: Identification of 14-3-3σ as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66: 3248, 2006.
71. Gast MC, Schellens JH and Beijnen JH: Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116: 17-29, 2009.
72. Yiu CC, Chanplakorn N, Chan MS, et al: Down regulation of heat shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor (AI) therapy in breast cancer patients. Anticancer Res 30: 3465-3472, 2010.
73. You BC, Park SP, Lee YD, et al: The expression of heat shock protein 60 kDa in tissues and cell lines of breast cancer. Breast Cancer 11: 161-171, 2008.
74. Zagouri F, Sergentanis TN, Nonni A, et al: Hsp90 in the continuum of breast ductal carcinogenesis: evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer 10: 353, 2010.
75. Goncalves A and Bertucci F: Clinical application of proteomics in breast cancer: state of the art and perspectives. Med Princ Prac 20: 4-18, 2011.
76. Haris L, Fritsche H, Mannel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 1-26, 2007.
77. Makridakis M and Vlahou A: Secretome proteomics for discovery of cancer biomarkers. J Proteomics 73: 2291-2305, 2010.
78. Camp RL, Neumeister V, Rimm DL, et al: A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 26: 5630-5637, 2008.
79. Brennan DJ, Kelly C, Rexhepaj E, et al: Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics Proteomic 4: 121-134, 2007.
80. Hondermarck H, Tastet C, Yazidi-Belkoura El, et al: Proteomics of breast cancer: the quest for markers and therapeutic targets. J Proteome Res 7: 1403-1411, 2008.
81. Gilabert M, Audebert S, Viens P, et al: Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers. Bull Cancer 97: 321-339, 2010.
82. Rodenhiser DI, Andrews JD, Vandenberg TA and Chambers AF: Gene signatures of breast cancer progression and metastasis. Breast Cancer Res 13: 201, 2011.
83. Tuck MK, Chan DW, Chia D, et al: Standard operating procedures for serum and plasma collection:early detection research net work consensus statement standard operating procedure integration working group. J Proteome Res 8: 113-117, 2009.
84. Callesen AK, Vach W, Jorgensen PE, et al: Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J Proteome Res 7: 1395-1402, 2008.
85. Zeidan BA, Cutress RI, Murray N, et al: Proteomic analysis of archival breast cancer serum. Cancer Genomics Proteomics 6: 141-147, 2009.